

(FILE 'USPAT' ENTERED AT 18:33:36 ON 28 SEP 1998)

L1 1 S ADVANCED GLYCATION END PRODUCT  
L2 16 S ADVANCED GLYCOSYLATION END PRODUCT  
L3 0 S L2(P)RECEPTOR  
L4 0 S L2 AND RECEPTOR  
L5 8 S L2 AND ATHEROSCLEROSIS

=> d L5 1-

1. 5,356,895, Oct. 18, 1994, 1,4 piperizino inhibitors of non-enzymatic cross-linking of proteins; Peter C. Ulrich, et al., 514/255; 544/402 [IMAGE AVAILABLE]
2. 5,334,617, Aug. 2, 1994, Amino acids useful as inhibitors of the advanced glycosylation of proteins; Peter C. Ulrich, et al., 514/562, 561, 564, 567, 824, 825, 866 [IMAGE AVAILABLE]
3. 5,238,963, Aug. 24, 1993, Method and agents for inhibiting protein aging; Anthony Cerami, et al., 514/632, 866 [IMAGE AVAILABLE]
4. 5,140,048, Aug. 18, 1992, Inhibitors of nonenzymatic cross-linking; Peter C. Ulrich, et al., 514/601; 424/400, 401; 426/268, 269, 320, 321; 514/614 [IMAGE AVAILABLE]
5. 5,128,360, Jul. 7, 1992, Method and agents for inhibiting protein aging; Anthony Cerami, et al., 514/400, 632, 634, 866 [IMAGE AVAILABLE]
6. 4,983,604, Jan. 8, 1991, Inhibitors of nonenzymatic cross-linking; Peter C. Ulrich, et al., 514/238.5; 544/162 [IMAGE AVAILABLE]
7. 4,908,446, Mar. 13, 1990, Inhibitors of nonenzymatic cross-linking; Peter C. Ulrich, et al., 540/553; 544/330; 548/331.1 [IMAGE AVAILABLE]
8. 4,758,583, Jul. 19, 1988, Method and agents for inhibiting protein aging; Anthony Cerami, et al., 514/399; 435/260; 514/561, 631; 564/230 [IMAGE AVAILABLE]

US PAT NO: 5,468,777 [IMAGE AVAILABLE] L2: 1 of 16  
DATE ISSUED: Nov. 21, 1995  
TITLE: Method and agents for preventing and reversing the  
staining of teeth  
INVENTOR: Dennis S. France, Morris Plains, NJ  
Anthony Cerami, Shelter Island, NY  
Peter C. Ulrich, Old Tappan, NJ  
Laura A. Norton, Ridgewood, NJ  
David L. Neer, Allendale, NJ  
ASSIGNEE: The Rockefeller University, New York, NY (U.S. corp.)  
Alteon Inc., Ramsey, NJ (U.S. corp.)  
APPL-NO: 08/236,228  
DATE FILED: Apr. 29, 1994  
ART-UNIT: 125  
PRIM-EXMR: Kimberly R. Jordan  
LEGAL-REP: Klauber & Jackson

US PAT NO: 5,468,777 [IMAGE AVAILABLE] L2: 1 of 16

ABSTRACT:

The present invention relates to methods and agents for preventing and reversing the staining of teeth caused by the nonenzymatic browning of proteins in the oral cavity. Suitable agents for the inhibition of nonenzymatic browning may be formulated as rinses and toothpastes, and include cysteine and cysteine derivatives. These preparations may further include known anti-plaque agents, such as chlorhexidine.

US PAT NO: 5,399,560 [IMAGE AVAILABLE] L2: 2 of 16  
DATE ISSUED: Mar. 21, 1995  
TITLE: 1,2,4-triazine products resulting from the inhibition of  
advanced glycosylation  
INVENTOR: Anthony Cerami, Shelter Island, NY  
Hauh-Jyun C. Chen, White Plains, NY  
ASSIGNEE: The Rockefeller University, New York, NY (U.S. corp.)  
APPL-NO: 07/956,722  
DATE FILED: Oct. 1, 1992  
ART-UNIT: 122  
PRIM-EXMR: Mukund J. Shah  
ASST-EXMR: Y. N. Gupta  
LEGAL-REP: Klauber & Jackson

US PAT NO: 5,399,560 [IMAGE AVAILABLE] L2: 2 of 16

ABSTRACT:

The mechanism of the inhibition of advanced glycosylation by aminoguanidine and other hydrazine type compounds was investigated using a solution of one or two molecules of aminoguanidine or other hydrazine type compound incubated with an Amadori product (1-propylamine-1-deoxy-D-fructose) under physiological conditions. This inhibition was found to proceed through the reactive intermediate 1-propylamino-1, 4-dideoxyosone to form the corresponding triazine and the dehydrazone of 1,4-dideoxyglucosone, respectively.

The triazine and dehydrazone products are useful as macrophage stimulants to activate a macrophage to effect removal of advanced glycosylation endproducts (AGEs). Additionally, they can be used in a variety of investigative methods in an effort to measure the extent of nonenzymatic glycosylation of a protein sample wherein aminoguanidine or other hydrazine-type compound is or was present during the glycosylation

process.

US PAT NO: 5,356,895 [IMAGE AVAILABLE] L2: 3 of 16  
DATE ISSUED: Oct. 18, 1994  
TITLE: 1,4 piperizino inhibitors of non-enzymatic cross-linking  
of proteins  
INVENTOR: Peter C. Ulrich, Tenafly, NJ  
Anthony Cerami, Shelter Island, NY  
ASSIGNEE: The Rockefeller University, New York, NY (U.S. corp.)  
APPL-NO: 07/889,141  
DATE FILED: May 27, 1992  
ART-UNIT: 121  
PRIM-EXMR: David B. Springer  
LEGAL-REP: Klauber & Jackson

US PAT NO: 5,356,895 [IMAGE AVAILABLE] L2: 3 of 16

ABSTRACT:

The present invention relates to compositions and methods for inhibiting nonenzymatic cross-linking (protein aging). Accordingly, a composition is disclosed which comprises; an agent capable of inhibiting the formation of advanced glycosylation endproducts of target proteins by reacting with the carbonyl moiety of the early glycosylation product of such target proteins formed by their initial glycosylation. Suitable agents contain an active nitrogen-containing group, such as a hydrazine group. Particular agents comprise aminoguanidine derivatives. the method comprises contacting the target protein with the composition. Both industrial and therapeutic applications for the invention are envisioned, as food spoilage and animal protein aging can be treated.

US PAT NO: 5,352,815 [IMAGE AVAILABLE] L2: 4 of 16  
DATE ISSUED: Oct. 4, 1994  
TITLE: Agent for suppression and interception of mailard reaction  
INVENTOR: Norihiro Kakimoto, Tokyo, Japan  
Kunie Nakamura, Kanagawa, Japan  
ASSIGNEE: Asai Germanium Research Institute Co., Ltd., Tokyo, Japan  
(foreign corp.)  
APPL-NO: 08/031,997  
DATE FILED: Mar. 16, 1993  
ART-UNIT: 124  
PRIM-EXMR: Jose G. Dees  
ASST-EXMR: Porfirio Nazario-Gonzalez  
LEGAL-REP: Burns, Doane, Swecker & Mathis

US PAT NO: 5,352,815 [IMAGE AVAILABLE] L2: 4 of 16

ABSTRACT:

The present invention provides an agent for suppression or interception of the Mailard reaction, which comprises, as the active component, an organogermanium compound represented by formula (1): ##STR1## wherein R.sub.1 to R.sub.3 may be the same or different and each of them represents a hydrogen atom, a lower alkyl group, or a phenyl group; and X represents a hydroxyl group, an O-lower alkyl group, an amino group, or a salt represented by OY (Y is a metal or a basic group-containing compound).

Said agent can effectively suppress or intercept the Mailard reaction and has high safety even when administered for a long period of time.

US PAT NO: 5,334,617 [IMAGE AVAILABLE] L2: 5 of 16  
DATE ISSUED: Aug. 2, 1994  
TITLE: Amino acids useful as inhibitors of the advanced  
glycosylation of proteins  
INVENTOR: Peter C. Ulrich, Old Tappan, NJ

ASSIGNEE: Anthony Cerami, Shelter Island, NY  
The Rockefeller University, New York, NY (U.S. corp.)  
Alteon Inc., Northvale, NJ (U.S. corp.)  
APPL-NO: 07/825,598  
DATE FILED: Jan. 27, 1992  
ART-UNIT: 125  
PRIM-EXMR: Frederick E. Waddell  
ASST-EXMR: Kimberly R. Jordan  
LEGAL-REP: Klauber & Jackson

US PAT NO: 5,334,617 [IMAGE AVAILABLE]

L2: 5 of 16

ABSTRACT:

The present invention relates to compositions and methods for inhibiting protein aging. Accordingly, a composition is disclosed which comprises an agent or compound capable of inhibiting the formation of advanced glycosylation end products of target proteins by reacting with the carbonyl moiety of the early glycosylation product of such target proteins formed by their initial glycosylation. Suitable agents are amino acids and their derivatives which contain an active nitrogen-containing group. Particular agents comprise lysine and mixtures thereof. The method comprises contacting the target protein with the composition. Both industrial and therapeutic applications for the invention are envisioned, as food spoilage and animal protein aging can be treated.

US PAT NO: 5,238,963 [IMAGE AVAILABLE] L2: 6 of 16  
DATE ISSUED: Aug. 24, 1993  
TITLE: Method and agents for inhibiting protein aging  
INVENTOR: Anthony Cerami, Shelter Island, NY  
Peter C. Ulrich, Tenafly, NJ  
Michael Brownlee, New York, NY  
ASSIGNEE: The Rockefeller University, New York, NY (U.S. corp.)  
APPL-NO: 07/805,200  
DATE FILED: Dec. 10, 1991  
ART-UNIT: 125  
PRIM-EXMR: Frederick E. Waddell  
ASST-EXMR: Kimberly R. Jordan  
LEGAL-REP: Klauber & Jackson

US PAT NO: 5,238,963 [IMAGE AVAILABLE]

L2: 6 of 16

ABSTRACT:

The present invention relates to compositions and methods for inhibiting protein aging. Accordingly, a composition is disclosed which comprises an agent or compound capable of inhibiting the formation of advanced glycosylation end products of target proteins by reacting with the carbonyl moiety of the early glycosylation product of such target proteins formed by their initial glycosylation. Suitable agents may contain an active nitrogen-containing group, such as a hydrazine group. Particular agents comprise aminoguanidine, .alpha.-hydrazinohistidine and mixtures thereof. The method comprises contacting the target protein with the composition. Both industrial and therapeutic applications for the invention are envisioned, as food spoilage and animal protein aging can be treated.

This invention was made in part with government support under Grant Number PHS AM 19655 awarded by the National Institutes of Health. The government has certain rights in the invention.

US PAT NO: 5,140,048 [IMAGE AVAILABLE] L2: 7 of 16  
DATE ISSUED: Aug. 18, 1992  
TITLE: Inhibitors of nonenzymatic cross-linking  
INVENTOR: Peter C. Ulrich, Tenafly, NJ  
Anthony Cerami, Shelter Island, NY

ASSIGNEE: The Rockefeller University, New York, NY (U.S. corp.)  
APPL-NO: 07/605,  
DATE FILED: Oct. 30, 1990  
ART-UNIT: 111  
PRIM-EXMR: Prince Willis, Jr.  
ASST-EXMR: Jerry D. Johnson  
LEGAL-REP: Klauber & Jackson

US PAT NO: 5,140,048 [IMAGE AVAILABLE]

L2: 7 of 16

ABSTRACT:

The present invention relates to compositions and methods for inhibiting nonenzymatic cross-linking (protein aging). Accordingly, a composition is disclosed which comprises; an agent capable of inhibiting the formation of advanced glycosylation endproducts of target proteins by reacting with the carbonyl moiety of the early glycosylation product of such target proteins formed by their initial glycosylation. Suitable agents contain an active nitrogen-containing group, such as a hydrazine group. Particular agents comprise aminoguanidine derivatives. The method comprises contacting the target protein with the composition. Both industrial and therapeutic applications for the invention are envisioned, as food spoilage and animal protein aging can be treated.

US PAT NO: 5,128,360 [IMAGE AVAILABLE] L2: 8 of 16  
DATE ISSUED: Jul. 7, 1992  
TITLE: Method and agents for inhibiting protein aging  
INVENTOR: Anthony Cerami, Shelter Island, NY  
Peter C. Ulrich, Tenafly, NJ  
Michael Brownlee, New York, NY  
ASSIGNEE: The Rockefeller University, New York, NY (U.S. corp.)  
APPL-NO: 07/481,869  
DATE FILED: Feb. 20, 1990  
ART-UNIT: 125  
PRIM-EXMR: Frederick E. Waddell  
ASST-EXMR: Kimberly R. Jordan  
LEGAL-REP: Klauber & Jackson

US PAT NO: 5,128,360 [IMAGE AVAILABLE]

L2: 8 of 16

ABSTRACT:

The present invention relates to compositions and methods for inhibiting protein aging. Accordingly, a composition is disclosed which comprises an agent or compound capable of inhibiting the formation of advanced glycosylation end products of target proteins by reacting with the carbonyl moiety of the early glycosylation product of such target proteins formed by their initial glycosylation. Suitable agents may contain an active nitrogen-containing group, such as a hydrazine group. Particular agents comprise aminoguanidine, .alpha.-hydrazinohistidine and mixtures thereof. The method comprises contacting the target protein with the composition. Both industrial and therapeutic applications for the invention are envisioned, as food spoilage and animal protein aging can be treated.

US PAT NO: 5,128,122 [IMAGE AVAILABLE] L2: 9 of 16  
DATE ISSUED: Jul. 7, 1992  
TITLE: Method and agents for preventing staining of teeth  
INVENTOR: Anthony Cerami, Shelter Island, NY  
Michael A. Yamin, Tappan, NY  
ASSIGNEE: The Rockefeller University, New York, NY (U.S. corp.)  
APPL-NO: 07/604,820  
DATE FILED: Oct. 26, 1990  
ART-UNIT: 183  
PRIM-EXMR: Ronald W. Griffin  
LEGAL-REP: Klauber & Jackson

## ABSTRACT:

The present invention relates to methods and agents for preventing the staining of teeth caused by the nonenzymatic browning of proteins in the oral cavity. Both oral and parenteral administration of the agents are disclosed. Suitable agents for the inhibition of nonenzymatic browning may be formulated as rinses and toothpastes, and include compounds capable of reacting with the carbonyl moiety of the early glycosylation product resulting from the initial reaction of a target protein in the nonenzymatic browning reaction. Preferred agents are those having an active nitrogen-containing substituent, as well as amino acids, their esters and amides. These preparations may further include known anti-plaque agents such as chlorhexidine.

US PAT NO: 5,126,442 [IMAGE AVAILABLE] L2: 10 of 16  
DATE ISSUED: Jun. 30, 1992  
TITLE: Advanced glycosylation endproducts and associated methods  
INVENTOR: James G. Farmar, New York, NY  
Peter Ulrich, New York, NY  
Anthony Cerami, Shelter Island, NY  
ASSIGNEE: The Rockefeller University, New York, NY (U.S. corp.)  
APPL-NO: 07/638,735  
DATE FILED: Jan. 8, 1991  
ART-UNIT: 183  
PRIM-EXMR: Ronald W. Griffin  
LEGAL-REP: Klauber & Jackson

US PAT NO: 5,126,442 [IMAGE AVAILABLE] L2: 10 of 16

## ABSTRACT:

New and useful chromophores have been isolated from the reaction mixture of proteins exposed to reducing sugars in the presence of sulfite over time. The chromophores are believed to be intermediates in nonenzymatic polypeptide glycosylation. The measurement of this chromophore makes possible both qualitative and quantitative assessment of the presence of nonenzymatic browning. Diagnostic and test kits are also disclosed.

US PAT NO: 5,017,696 [IMAGE AVAILABLE] L2: 11 of 16  
DATE ISSUED: May 21, 1991  
TITLE: Advanced glycosylation end products and associated methods  
INVENTOR: James G. Farmar, New York, NY  
Peter Ulrich, New York, NY  
Anthony Cerami, Shelter Island, NY  
ASSIGNEE: The Rockefeller University, New York, NY (U.S. corp.)  
APPL-NO: 07/453,935  
DATE FILED: Dec. 20, 1989  
ART-UNIT: 183  
PRIM-EXMR: Ronald W. Griffin  
LEGAL-REP: Klauber & Jackson

US PAT NO: 5,017,696 [IMAGE AVAILABLE] L2: 11 of 16

## ABSTRACT:

New and useful chromophores have been isolated from the reaction mixture of proteins exposed to reducing sugars in the presence of sulfite over time. The chromophores are believed to be intermediates in nonenzymatic polypeptide glycosylation. The measurement of this chromophore makes possible both qualitative and quantitative assessment of the presence of nonenzymatic browning. Diagnostic and test kits are also disclosed.

US PAT NO: 4,983,604 [IMAGE AVAILABLE] L2: 12 of 16

DATE ISSUED: Jan. 8, 1991  
TITLE: Inhibitors of nonenzymatic cross-linking  
INVENTOR: Peter C. Ulrich, New York, NY  
Anthony Cerami, Shelter Island, NY  
ASSIGNEE: The Rockefeller University, New York, NY (U.S. corp.)  
APPL-NO: 07/264,930  
DATE FILED: Nov. 2, 1988  
ART-UNIT: 117  
PRIM-EXMR: O. Chaudhuri  
ASST-EXMR: Jerry D. Johnson  
LEGAL-REP: Klauber & Jackson

US PAT NO: 4,983,604 [IMAGE AVAILABLE]

L2: 12 of 16

ABSTRACT:

The present invention relates to compositions and methods for inhibiting nonenzymatic cross-linking (protein aging). Accordingly, a composition is disclosed which comprises an agent capable of inhibiting the formation of advanced glycosylation endproducts of target proteins by reacting with the carbonyl moiety of the early glycosylation product of such target proteins formed by their initial glycosylation. Suitable agents contain an active nitrogen-containing group, such as a hydrazine group. Particular agents comprise aminoguanidine derivatives. The method comprises contacting the target protein with the composition. Both industrial and therapeutic applications for the invention are envisioned, as food spoilage and animal protein aging can be treated.

US PAT NO: 4,908,446 [IMAGE AVAILABLE] L2: 13 of 16  
DATE ISSUED: Mar. 13, 1990  
TITLE: Inhibitors of nonenzymatic cross-linking  
INVENTOR: Peter C. Ulrich, New York, NY  
Anthony Cerami, Shelter Island, NY  
ASSIGNEE: The Rockefeller University, New York, NY (U.S. corp.)  
APPL-NO: 07/119,958  
DATE FILED: Nov. 13, 1987  
ART-UNIT: 118  
PRIM-EXMR: William R. Dixon, Jr.  
ASST-EXMR: Jerry D. Johnson  
LEGAL-REP: Klauber & Jackson

US PAT NO: 4,908,446 [IMAGE AVAILABLE]

L2: 13 of 16

ABSTRACT:

The present invention relates to compositions and methods for inhibiting nonenzymatic cross-linking (protein aging). Accordingly, a composition is disclosed which comprises an agent capable of inhibiting the formation of advanced glycosylation endproducts of target proteins by reacting with the carbonyl moiety of the early glycosylation product of such target proteins formed by their initial glycosylation. Suitable agents contain an active nitrogen-containing group, such as a hydrazine group. Particular agents comprise aminoguanidine derivatives. The method comprises contacting the target protein with the composition. Both industrial and therapeutic applications for the invention are envisioned, as food spoilage and animal protein aging can be treated.

US PAT NO: 4,761,368 [IMAGE AVAILABLE] L2: 14 of 16  
DATE ISSUED: Aug. 2, 1988  
TITLE: Method and agents for measuring protein aging  
INVENTOR: Anthony Cerami, Flanders, NJ  
ASSIGNEE: The Rockefeller University, New York, NY (U.S. corp.)  
APPL-NO: 06/885,967  
DATE FILED: Jul. 15, 1986  
ART-UNIT: 128  
PRIM-EXMR: Sidney Marantz

ASST-EXMR: Richard Wagner  
LEGAL-REP: Klaube Jackson

US PAT NO: 4,761,368 [IMAGE AVAILABLE]

L2: 14 of 16

ABSTRACT:

A new and useful fluorescent chromophore has been isolated and identified which has been observed in proteins exposed to glucose over time, and whose fluorescent properties closely resemble those of the polypeptide after it undergoes advanced glycosylation. The chromophore has been structurally identified and named 2-furoyl-4(5)-(2-furanyl)-1H-imidazole, and is believed to be one of the end products of extended nonenzymatic polypeptide glycosylation, which results in the state known as nonenzymatic browning (NEB). The measurement of this chromophore makes possible both qualitative and quantitative assessment of the degree of aging. Diagnostic and test kits are also disclosed.

US PAT NO: 4,758,583 [IMAGE AVAILABLE]

L2: 15 of 16

DATE ISSUED: Jul. 19, 1988

TITLE: Method and agents for inhibiting protein aging

INVENTOR: Anthony Cerami, Flanders, NJ

Peter C. Ulrich, New York, NY

Michael Brownlee, New York, NY

ASSIGNEE: The Rockefeller University, New York, NY (U.S. corp.)

APPL-NO: 06/798,032

DATE FILED: Nov. 14, 1985

ART-UNIT: 125

PRIM-EXMR: Stanley J. Friedman

LEGAL-REP: David A. Jackson, Richard M. Goldberg, Barbara L. Renda

US PAT NO: 4,758,583 [IMAGE AVAILABLE]

L2: 15 of 16

ABSTRACT:

The present invention relates to compositions and methods for inhibiting protein aging. Accordingly, a composition is disclosed which comprises an agent or compound capable of inhibiting the formation of advanced glycosylation end products of target proteins by reacting with the carbonyl moiety of the early glycosylation product of such target proteins formed by their initial glycosylation. Suitable agents may contain an active nitrogen-containing group, such as a hydrazine group, and may further be at least partially derived from amino acids. Particular agents comprise aminoguanidine, .alpha.-hydrazinohistidine and lysine. The method comprises contacting the target protein with the composition. Both industrial and therapeutic applications for the invention are envisioned, as food spoilage and animal protein aging can be treated.

US PAT NO: 4,665,192 [IMAGE AVAILABLE]

L2: 16 of 16

DATE ISSUED: May 12, 1987

TITLE: 2-(2-furoyl)-4(5)-2(furanyl)-1H-imidazole

INVENTOR: Anthony Cerami, Flanders, NJ

ASSIGNEE: The Rockefeller University, New York, NY (U.S. corp.)

APPL-NO: 06/590,820

DATE FILED: Mar. 19, 1984

ART-UNIT: 121

PRIM-EXMR: Richard A. Schwartz

LEGAL-REP: David A. Jackson

US PAT NO: 4,665,192 [IMAGE AVAILABLE]

L2: 16 of 16

ABSTRACT:

A new and useful fluorescent chromophore has been isolated and identified which has been observed in proteins exposed to glucose over time, and whose fluorescent properties closely resemble those of the polypeptide



after it undergoes advanced glycosylation. The chromophore has been structurally identified and named 2-(2-furoyl)-4(5)-2(furoyl)-1H-imidazole, and is believed to be one of the end products of extended nonenzymatic polypeptide glycosylation, which results in the state known as nonenzymatic browning (NEB). The measurement of this chromophore makes possible both qualitative and quantitative assessment of the degree of aging. Diagnostic and test kits are also disclosed.

medline, CAPUS, WPIJS

9/28/98

=> s advanced glycation end product

L1 202 ADVANCED GLYCATION END PRODUCT

=> s advanced glycosylation end product

L2 387 ADVANCED GLYCOSYLATION END PRODUCT

=> s l1 or l2

L3 534 L1 OR L2

=> s L3 and receptor

L4 196 L3 AND RECEPTOR

=> s l4 and vascular

L5 71 L4 AND VASCULAR

=> s l4 and atherosclerosis

L6 40 L4 AND ATHEROSCLEROSIS

=> dup rem l6

PROCESSING COMPLETED FOR L6

L7 34 DUP REM L6 (6 DUPLICATES REMOVED)

YOU HAVE REQUESTED DATA FROM 34 ANSWERS - CONTINUE? Y/(N):y

L7 ANSWER 1 OF 34 MEDLINE DUPLICATE 1  
AN 1998202099 MEDLINE  
DN 98202099  
TI Advanced glycosylation end products induced tissue factor expression  
in human monocyte-like U937 cells and increased tissue factor  
expression in monocytes from diabetic patients.  
AU Ichikawa K; Yoshinari M; Iwase M; Wakisaka M; Doi Y; Iino K;  
Yamamoto M; Fujishima M  
CS Second Department of Internal Medicine, Faculty of Medicine, Kyushu  
University, Fukuoka, Japan.  
SO ATHEROSCLEROSIS, (1998 Feb) 136 (2) 281-7.  
Journal code: 95X. ISSN: 0021-9150.  
CY Ireland  
DT Journal; Article; (JOURNAL ARTICLE)  
LA English  
FS Priority Journals  
EM 199807  
EW 19980705

L7 ANSWER 2 OF 34 CAPLUS COPYRIGHT 1998 ACS  
AN 1998:116256 CAPLUS  
DN 128:152392  
TI Biological significance of glycation  
AU Nagai, Ryoji; Sano, Hiroyuki; Horiuchi, Seikoh  
CS Sch. Med., Kumamoto Univ., Kumamoto, 860, Japan  
SO Kagaku to Seibutsu (1998), 36(2), 83-88  
CODEN: KASEAA; ISSN: 0453-073X  
PB Gakkai Shuppan Senta  
DT Journal; General Review  
LA Japanese

L7 ANSWER 3 OF 34 CAPLUS COPYRIGHT 1998 ACS DUPLICATE 2  
AN 1997:696868 CAPLUS  
DN 128:2908  
TI Antibodies against the **advanced glycosylation  
end-product receptor** and uses thereof  
IN Morser, Michael John; Nagashima, Mariko; Hollander, Doris Anne  
PA Schering Aktiengesellschaft Patente, Germany  
SO PCT Int. Appl., 89 pp.  
CODEN: PIXXD2  
PI WO 9739125 A1 19971023  
DS W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE,  
ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS,  
LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD,  
SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, AM, AZ, BY, KG,  
KZ, MD, RU, TJ, TM  
RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, DE, DK, ES, FI, FR, GA, GB,  
GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG  
AI WO 97-EP1834 19970411  
PRAI US 96-633148 19960416  
DT Patent  
LA English

L7 ANSWER 4 OF 34 CAPLUS COPYRIGHT 1998 ACS DUPLICATE 3  
AN 1997:696864 CAPLUS  
DN 128:10317

TI **Advanced glycosylation end-product receptor** provides and their uses for increasing vascular permeability in disease conditions  
 IN Morser, Michael John; Nagashima, Mariko  
 PA Schering Aktiengesellschaft, Germany  
 SO PCT Int. Appl., 91 pp.  
 CODEN: PIXXD2  
 PI WO 9739121 A1 19971023  
 DS W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM  
 RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG  
 AI WO 97-EP1832 19970411  
 PRAI US 96-633147 19960416  
 DT Patent  
 LA English

L7 ANSWER 5 OF 34 WPIDS COPYRIGHT 1998 DERWENT INFORMATION LTD  
 AN 97-393374 [36] WPIDS  
 DNC C97-126340  
 TI Inhibiting damage to cells in e.g. Alzheimer's disease - using an agent which inhibits interaction of an amyloid-beta peptide with a **receptor for advanced glycosylation end product.**  
 DC B04 D16  
 IN SCHMIDT, A M; STERN, D; YAN, S D  
 PA (UYCO) UNIV COLUMBIA NEW YORK  
 CYC 21  
 PI WO 9726913 A1 970731 (9736)\* EN 91 pp A61K039-395  
 RW: AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE  
 W: AU CA JP MX  
 AU 9718327 A 970820 (9749) A61K039-395  
 ADT WO 9726913 A1 WO 97-US857 970121; AU 9718327 A AU 97-18327 970121  
 FDT AU 9718327 A Based on WO 9726913  
 PRAI US 96-592070 960126  
 IC ICM A61K039-395  
 ICS A61K038-00; C07K016-00

L7 ANSWER 6 OF 34 WPIDS COPYRIGHT 1998 DERWENT INFORMATION LTD  
 AN 98-062326 [06] WPIDS  
 CR 85-249222 [40]; 87-137378 [20]; 90-098908 [13]; 92-131583 [16]; 92-159422 [19]; 92-192216 [23]; 92-249455 [30]; 92-258953 [31]; 92-258959 [31]; 93-213460 [26]; 93-258353 [32]; 93-280695 [35]; 93-295311 [37]; 93-345003 [43]; 93-377384 [47]; 93-413441 [51]; 94-182638 [22]; 94-217082 [26]; 94-302650 [37]; 94-332366 [41]; 94-341036 [42]; 96-048998 [05]; 96-086502 [09]; 96-320533 [32]; 98-229760 [20]; 98-229866 [20]  
 DNN N98-049080 DNC C98-021692  
 TI Estimation of lipid oxidation in vivo - by assay for AGE-lipid(s), useful for monitoring and diagnosing vascular disease.  
 DC B04 D16 S03  
 IN BUCALA, R J; CERAMI, A; TRACEY, K J; VLASSARA, H  
 PA (PICO-N) PICOWER INST MEDICAL RES  
 CYC 1  
 PI US 5700447 A 971223 (9806)\* 37 pp G01N033-48  
 ADT US 5700447 A CIP of US 92-887279 920521, CIP of US 93-29417 930311, US 94-319747 941007  
 PRAI US 94-319747 941007; US 92-887279 920521; US 93-29417 930311  
 IC ICM G01N033-48

L7 ANSWER 7 OF 34 MEDLINE DUPLICATE 4  
 AN 1998012750 MEDLINE  
 DN 98012750

TI Effect of streptozotocin-induced hyperglycemia on lipid profiles, formation of advanced glycation endproducts in lesions, and extent of **atherosclerosis** in LDL **receptor**-deficient mice.

AU Reaven P; Merat S; Casanada F; Sutphin M; Palinski W

CS Department of Medicine, University of California, San Diego, La Jolla, 92093-0682, USA.

NC HL-14197 (NHLBI)

SO ARTERIOSCLEROSIS, THROMBOSIS, AND VASCULAR BIOLOGY, (1997 Oct) 17 (10) 2250-6.

Journal code: B89. ISSN: 1079-5642.

CY United States

DT Journal; Article; (JOURNAL ARTICLE)

LA English

FS Priority Journals

EM 199801

EW 19980104

L7 ANSWER 8 OF 34 MEDLINE DUPLICATE 5

AN 97465000 MEDLINE

DN 97465000

TI Elevated AGE-modified ApoB in sera of euglycemic, normolipidemic patients with **atherosclerosis**: relationship to tissue AGEs.

AU Stitt A W; He C; Friedman S; Scher L; Rossi P; Ong L; Founds H; Li Y M; Bucala R; Vlassara H

CS Picower Institute for Medical Research, Manhasset, New York, USA.

NC AG09453 (NIA)

AG06943 (NIA)

SO MOLECULAR MEDICINE, (1997 Sep) 3 (9) 617-27.

Journal code: CG3. ISSN: 1076-1551.

CY United States

DT Journal; Article; (JOURNAL ARTICLE)

LA English

FS Priority Journals

EM 199801

EW 19980104

L7 ANSWER 9 OF 34 CAPLUS COPYRIGHT 1998 ACS

AN 1997:146011 CAPLUS

DN 126:249779

TI The **receptor** for advanced glycation end products mediates the chemotaxis of rabbit smooth muscle cells

AU Higashi, Takayuki; Sano, Hiroyuki; Saishoji, Tewtsushi; Ikeda, Kazuyoshi; Jinnouchi, Yoshiteru; Kanzaki, Tetsuto; Morisaki, Nobuhiro; Rauvala, Heikki; Shichiri, Motoaki; Horiuchi, Seikoh

CS Departments Biochemistry and Metabolic Medicine, Kumamoto Univ. School Medicine, Kumamoto, 860, Japan

SO Diabetes (1997), 46(3), 463-472

CODEN: DIAEAZ; ISSN: 0012-1797

PB American Diabetes Association, Inc.

DT Journal

LA English

L7 ANSWER 10 OF 34 CAPLUS COPYRIGHT 1998 ACS

AN 1997:249716 CAPLUS

DN 126:315557

TI What's the RAGE? The **receptor** for advanced glycation end products (RAGE) and the dark side of glucose

AU Yan, S. D.; Stern, D.; Schmidt, A. M.

CS Departments of Pathology, Surgery, Physiology and Medicine, College of Physicians and Surgeons, Columbia University, New York, NY, 10032, USA

SO Eur. J. Clin. Invest. (1997), 27(3), 179-181

CODEN: EJCIB8; ISSN: 0014-2972

PB Blackwell

DT Journal; General Review  
LA English

L7 ANSWER 11 OF 34 CAPLUS COPYRIGHT 1998 ACS

AN 1997:437490 CAPLUS

DN 127:107242

TI Atherogenesis and advanced glycation: promotion, progression, and prevention

AU Stitt, Alan W.; Bucala, Richard; Vlassara, Helen

CS The Picower Institute for Medical Research, Manhasset, NY, 11030, USA

SO Ann. N. Y. Acad. Sci. (1997), 811(Atherosclerosis IV: Recent Advances in Atherosclerosis Research), 115-129

CODEN: ANYAA9; ISSN: 0077-8923

PB New York Academy of Sciences

DT Journal; General Review

LA English

L7 ANSWER 12 OF 34 CAPLUS COPYRIGHT 1998 ACS

AN 1997:180263 CAPLUS

DN 126:223591

TI Advanced glycation end products, oxidant stress and vascular lesions

AU Chappey, O.; Dosquet, C.; Wautier, M-P.; Wautier, J-L.

CS Biologie Vasculaire et Cellulaire, Immunohematologie, Pariss, Fr.

SO Eur. J. Clin. Invest. (1997), 27(2), 97-108

CODEN: EJCIB8; ISSN: 0014-2972

PB Blackwell

DT Journal; General Review

LA English

L7 ANSWER 13 OF 34 CAPLUS COPYRIGHT 1998 ACS

AN 1998:311203 CAPLUS

DN 129:107222

TI Advanced glycosylation: role in **atherosclerosis**

AU Bucala, Richard

CS The Picower Institute for Medical Research, Manhasset, NY, USA

SO Glycation Hypothesis Atheroscler. (1997), 89-107. Editor(s): Colaco, Camilo A. L. S. Publisher: Landes Bioscience, Austin, Tex. CODEN: 66AXAH

DT Conference; General Review

LA English

L7 ANSWER 14 OF 34 MEDLINE

AN 97429856 MEDLINE

DN 97429856

TI Recent progress in advanced glycation end products and diabetic complications.

AU Vlassara H

CS Picower Institute for Medical Research, Manhasset, New York 11030, USA.

SO DIABETES, (1997 Sep) 46 Suppl 2 S19-25.

Journal code: E8X. ISSN: 0012-1797.

CY United States

DT Journal; Article; (JOURNAL ARTICLE)

LA English

FS Abridged Index Medicus Journals; Priority Journals

EM 199711

EW 19971104

L7 ANSWER 15 OF 34 MEDLINE

AN 96325216 MEDLINE

DN 96325216

TI Receptors for advance glycation end-products (AGE) - expression by endothelial cells in non-diabetic uraemic patients.

AU Greten J; Kreis I; Wiesel K; Stier E; Schmidt A M; Stern D M; Ritz E; Waldherr R; Nawroth P P

CS Department of Medicine, University of Heidelberg, Germany.  
 SO NEPHROLOGY, DIALYSIS, TRANSPLANTATION, (1996 May) 10(5) 786-90.  
 Journal code: N7J. ISSN: 0931-0509.  
 CY ENGLAND: United Kingdom  
 DT Journal; Article; (JOURNAL ARTICLE)  
 LA English  
 FS Priority Journals  
 EM 199612

L7 ANSWER 16 OF 34 CAPLUS COPYRIGHT 1998 ACS  
 AN 1996:532565 CAPLUS  
 DN 125:192089  
 TI Advanced glycation end products (AGE)-modified proteins and their potential relevance to **atherosclerosis**  
 AU Horiuchi, Seikoh  
 CS School Medicine, Kumamoto University, Kumamoto, 860, Japan  
 SO Trends Cardiovasc. Med. (1996), 6(5), 163-168  
 CODEN: TCMDEQ; ISSN: 1050-1738  
 DT Journal; General Review  
 LA English

L7 ANSWER 17 OF 34 CAPLUS COPYRIGHT 1998 ACS  
 AN 1996:604824 CAPLUS  
 DN 125:324992  
 TI Pathophysiological role of AGE in **atherosclerosis**  
 AU Higashi, Takayuki; Kume, Shuichi; Ikeda, Kazuyoshi; Saishoji, Tetsushi; Sano, Hiroyuki; Jinnouchi, Yoshiteru; Nagai, Ryoji; Takahashi, Kiyoshi; Shichiri, Motoaki; Horiuchi, Seikoh  
 CS Sch. Med., Kumamoto Univ., Kumamoto, 860, Japan  
 SO Domyaku Koka (1996), 24(3), 89-95  
 CODEN: DOMKDM; ISSN: 0386-2682  
 DT Journal  
 LA Japanese

L7 ANSWER 18 OF 34 MEDLINE  
 AN 97197254 MEDLINE  
 DN 97197254  
 TI Extra- and intracellular localization of advanced glycation end-products in human atherosclerotic lesions.  
 AU Horiuchi S; Sano H; Higashi T; Ikeda K; Jinnouchi Y; Nagai R; Takahashi K  
 CS Departments of Biochemistry, Kumamoto University School of Medicine, Japan.  
 SO NEPHROLOGY, DIALYSIS, TRANSPLANTATION, (1996) 11 Suppl 5 81-6. Ref: 36  
 Journal code: N7J. ISSN: 0931-0509.  
 CY ENGLAND: United Kingdom  
 DT Journal; Article; (JOURNAL ARTICLE)  
 General Review; (REVIEW)  
 (REVIEW, TUTORIAL)  
 LA English  
 FS Priority Journals  
 EM 199708  
 EW 19970801

L7 ANSWER 19 OF 34 CAPLUS COPYRIGHT 1998 ACS  
 AN 1996:560126 CAPLUS  
 DN 125:272538  
 TI Elucidation of the significance of advanced glycation end products (AGE) of Maillard reaction in diabetic complications and diseases based on aging  
 AU Araki, Norie; Shiga, Masanobu; Sakamoto, Tamami  
 CS Sch. Med., Kumamoto Univ., Kumamoto, 860, Japan  
 SO Sagawa Sentan Kagaku Gijutsu Shinko Zaidan Josei Kenkyu Hokokusho (1996), Volume Date 1995, 8th, 52-57  
 CODEN: SSKHFS; ISSN: 0919-0414

DT Journal  
LA Japanese

L7 ANSWER 20 OF 34 MEDLINE  
AN 95386695 MEDLINE  
DN 95386695  
TI Advanced glycation endproducts interacting with their endothelial **receptor** induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice. A potential mechanism for the accelerated vasculopathy of diabetes.  
AU Schmidt A M; Hori O; Chen J X; Li J F; Crandall J; Zhang J; Cao R; Yan S D; Brett J; Stern D  
CS Department of Medicine, Columbia University-College of Physicians and Surgeons, New York, New York 10032, USA..  
NC AG-00602 (NIA)  
HL-21006 (NHLBI)  
HL-42833 (NHLBI)  
+  
SO JOURNAL OF CLINICAL INVESTIGATION, (1995 Sep) 96 (3) 1395-403.  
Journal code: HS7. ISSN: 0021-9738.  
CY United States  
DT Journal; Article; (JOURNAL ARTICLE)  
LA English  
FS Abridged Index Medicus Journals; Priority Journals; Cancer Journals  
EM 199512

L7 ANSWER 21 OF 34 CAPLUS COPYRIGHT 1998 ACS  
AN 1995:615403 CAPLUS  
DN 123:80729  
TI Immunological evidence for the presence of advanced glycosylation end products in atherosclerotic lesions of euglycemic rabbits  
AU Palinski, Wulf; Koschinsky, Theodor; Butler, Susan W.; Miller, Elizabeth; Vlassara, Helen; Cerami, Anthony; Witztum, Joseph L.  
CS Department of Medicine, University of California, San Diego, La Jolla, CA, USA  
SO Arterioscler., Thromb., Vasc. Biol. (1995), 15(5), 571-82  
CODEN: ATVBFA; ISSN: 1079-5642  
DT Journal  
LA English

L7 ANSWER 22 OF 34 CAPLUS COPYRIGHT 1998 ACS  
AN 1995:630906 CAPLUS  
DN 123:80800  
TI Macrophage scavenger **receptor** mediates the endocytic uptake and degradation of advanced glycation end products of the Maillard reaction  
AU Araki, Norie; Higashi, Takayuki; Mori, Takashi; Shibayama, Rie; Kawabe, Yoshiki; Kodama, Tatsuhiko; Takahashi, Kiyoshi; Schichiri, Motoaki; Horiuchi, Seikoh  
CS Department of Biochemistry, Kumamoto University School of Medicine, Kumamoto, 860, Japan  
SO Eur. J. Biochem. (1995), 230(2), 408-15  
CODEN: EJBCAI; ISSN: 0014-2956  
DT Journal  
LA English

L7 ANSWER 23 OF 34 CAPLUS COPYRIGHT 1998 ACS  
AN 1996:93551 CAPLUS  
DN 124:171917  
TI Receptors for advanced glycation endproducts: in vivo role and human studies  
AU Vlassara, Helen  
CS Picower Institute Medical Research, Manhasset, NY, 11030, USA  
SO Int. Congr. Ser. (1995), 1100(Diabetes 1994), 286-91  
CODEN: EXMDA4; ISSN: 0531-5131  
DT Journal; General Review



LA English

L7 ANSWER 24 OF 34 CAPLUS COPYRIGHT 1998 ACS  
 AN 1995:844467 CAPLUS  
 DN 124:6213  
 TI Structures of advanced glycation end products and their role in pathophysiological states  
 AU Horiuchi, Seikoh; Higashi, Takayuki; Ikeda, Kazuyoshi; Saishoji, Tetsushi; Jinnouchi, Yoshiteru; Sano, Hiroyuki; Araki, Norie  
 CS School Medicine, Kumamoto University, Kumamoto, Japan  
 SO Contrib. Nephrol. (1995), 112(Dialysis-Related Amyloidosis), 32-41  
 CODEN: CNEPDD; ISSN: 0302-5144  
 DT Journal  
 LA English

L7 ANSWER 25 OF 34 CAPLUS COPYRIGHT 1998 ACS  
 AN 1994:676201 CAPLUS  
 DN 121:276201  
 TI Glycosylation of lipids and lipid-containing particles, and diagnostic and therapeutic methods and materials derived therefrom  
 IN Bucala, Richard J.; Vlassara, Helen; Cerami, Anthony  
 PA Picower Institute for Medical Research, USA  
 SO PCT Int. Appl., 99 pp.  
 CODEN: PIXXD2  
 PI WO 9420083 A1 19940915  
 DS W: AU, BB, BG, BR, BY, CA, CZ, FI, HU, JP, KP, KR, KZ, LK, MG, MN, MW, NO, NZ, PL, RO, RU, SD, SK, UA, VN  
 RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, DE, DK, ES, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG  
 AI WO 93-US10880 19931112  
 PRAI US 93-29417 19930311  
 DT Patent  
 LA English  
 OS MARPAT 121:276201

L7 ANSWER 26 OF 34 CAPLUS COPYRIGHT 1998 ACS  
 AN 1994:627858 CAPLUS  
 DN 121:227858  
 TI Modification of low density lipoprotein by advanced glycation end products contributes to the dyslipidemia of diabetes and renal insufficiency  
 AU Bucala, Richard; Makita, Zenji; Vega, Gloria; Grundy, Scott; Roschinsky, Theodor; Cerami, Anthony; Vlassara, Helen  
 CS The Picower Institute for Medical Research, Manhasset, NY, 11030, USA  
 SO Proc. Natl. Acad. Sci. U. S. A. (1994), 91(20), 9441-5  
 CODEN: PNASA6; ISSN: 0027-8424  
 DT Journal  
 LA English

L7 ANSWER 27 OF 34 CAPLUS COPYRIGHT 1998 ACS  
 AN 1994:698026 CAPLUS  
 DN 121:298026  
 TI Cellular receptors for advanced glycation end products: implications for induction of oxidant stress and cellular dysfunction in the pathogenesis of vascular lesions  
 AU Schmidt, Ann Marie; Hori, Osamu; Brett, Jerold; Yan, Shi Du; Wautier, Jean-Luc; Stern, David  
 CS College of Physicians and Surgeons, Columbia University, New York, NY, 10032, USA  
 SO Arterioscler. Thromb. (1994), 14(10), 1521-8  
 CODEN: ARTTE5; ISSN: 1049-8834  
 DT Journal; General Review  
 LA English

L7 ANSWER 28 OF 34 CAPLUS COPYRIGHT 1998 ACS

AN 1995:278135 CAPLUS  
 DN 122:233401  
 TI AGE-receptors and in vivo biological effects of AGEs  
 AU Vlassara, Helen  
 CS The Picower Institute for Medical Research, Manhasset/New York,  
 11030, USA  
 SO Spec. Publ. - R. Soc. Chem. (1994), 151(Maillard Reactions in  
 Chemistry, Food, and Health), 254-61  
 CODEN: SROCDO; ISSN: 0260-6291  
 DT Journal; General Review  
 LA English

L7 ANSWER 29 OF 34 MEDLINE  
 AN 94017190 MEDLINE  
 DN 94017190  
 TI Carbohydrate metabolism.  
 AU Iguchi A; Miura H; Sakamoto N  
 CS Department of Geriatric Medicine, Nagoya Univ. Sch. of Med..  
 SO NIPPON RINSHO. JAPANESE JOURNAL OF CLINICAL MEDICINE, (1993 Aug) 51  
 (8) 1961-6.  
 Journal code: KIM. ISSN: 0047-1852.  
 CY Japan  
 DT Journal; Article; (JOURNAL ARTICLE)  
 LA Japanese  
 EM 199401

L7 ANSWER 30 OF 34 CAPLUS COPYRIGHT 1998 ACS  
 AN 1994:240942 CAPLUS  
 DN 120:240942  
 TI Survey of the distribution of a newly characterized **receptor**  
 for advanced glycation end products in tissues  
 AU Brett, Jerold; Schmidt, Ann Marie; Yan, Shi Du; Zou, Yu Shan;  
 Weidman, Elliott; Pinsky, David; Nowygrod, Roman; Neeper, Michael;  
 Przysiecki, Craig; et al.  
 CS Coll. Physicians Surg., Columbia Univ., New York, NY, 10032, USA  
 SO Am. J. Pathol. (1993), 143(6), 1699-712  
 CODEN: AJPAA4; ISSN: 0002-9440  
 DT Journal  
 LA English

L7 ANSWER 31 OF 34 CAPLUS COPYRIGHT 1998 ACS  
 AN 1993:405414 CAPLUS  
 DN 119:5414  
 TI Monocyte/macrophage receptors for proteins modified by advanced  
 glycation end products: Role in normal tissue remodeling and in  
 pathology  
 AU Vlassara, H.  
 CS Lab. Med. Biochem., Rockefeller Univ., New York, NY, 10021-6399, USA  
 SO Mononucleated Phagocytes (1992), 193-201. Editor(s): Van Furth, Ralph.  
 Publisher: Kluwer, Dordrecht, Neth.  
 CODEN: 59AEA4  
 DT Conference; General Review  
 LA English

L7 ANSWER 32 OF 34 MEDLINE DUPLICATE 6  
 AN 92128692 MEDLINE  
 DN 92128692  
 TI Chromatographic quantitation of plasma and erythrocyte pentosidine  
 in diabetic and uremic subjects.  
 AU Odetti P; Fogarty J; Sell D R; Monnier V M  
 CS Institute of Pathology, Case Western Reserve University, Cleveland,  
 Ohio 44106..  
 NC AG 05601 (NIA)  
 EY 07099 (NEI)  
 SO DIABETES, (1992 Feb) 41 (2) 153-9.  
 Journal code: E8X. ISSN: 0012-1797.

CY United States  
DT Journal; Article (JOURNAL ARTICLE)  
LA English  
FS Abridged Index Medicus Journals; Priority Journals  
EM 199205

L7 ANSWER 33 OF 34 CAPLUS COPYRIGHT 1998 ACS  
AN 1992:405301 CAPLUS  
DN 117:5301  
TI Secretion of a chemotactic substance(s) by AGE-stimulated human monocytes  
AU Gilcrease, Michael Z.; Hoover, Richard L.  
CS Dep. Pathol., Vanderbilt Univ., Nashville, TN, 37232, USA  
SO Diabetes Res. Clin. Pract. (1992), 16(1), 7-11  
CODEN: DRCPE9; ISSN: 0168-8227  
DT Journal  
LA English

L7 ANSWER 34 OF 34 CAPLUS COPYRIGHT 1998 ACS  
AN 1990:530471 CAPLUS  
DN 113:130471  
TI Activated human monocytes exhibit **receptor**-mediated adhesion to a non-enzymically glycosylated protein substrate  
AU Gilcrease, M. Z.; Hoover, R. L.  
CS Dep. Pathol., Vanderbilt Univ., Nashville, TN, 37232, USA  
SO Diabetologia (1990), 33(6), 329-33  
CODEN: DBTG AJ; ISSN: 0012-186X  
DT Journal  
LA English